May 31 (Reuters) - Alpha Cognition Inc ACOG.V :
* ALPHA COGNITION INC - ON TRACK AND PLANS TO RELEASE DATA FROM ALPHA-1062 PIVOTAL TRIAL DURING Q2 OF 2022
* ALPHA COGNITION INC - PLANS TO MEET WITH FDA FOR ALPHA-1062 INTRANASAL FOR MTBI DURING Q3 OF 2022
* ALPHA COGNITION INC - Q1 2022 NET LOSS WAS $2.7 MILLION, OR A NET LOSS OF $0.04 PER SHARE
* ALPHA COGNITION INC - CASH, CASH EQUIVALENTS AS OF MARCH 31, 2022, WERE $9.1 MILLION
Source text for Eikon: ID:nBw2kCFj7a Further company coverage: ACOG.V